| | Can AI predict clinical trial outcomes? (baybridgebio.com) |
| 2 points by aaavl2821 8 months ago | past |
|
| | AI won't replace biotech analysts (baybridgebio.com) |
| 1 point by aaavl2821 8 months ago | past |
|
| | Show HN: Research Pharma Markets with AI (baybridgebio.com) |
| 2 points by aaavl2821 11 months ago | past |
|
| | Show HN: Search for drugs approved to treat a given disease (baybridgebio.com) |
| 1 point by aaavl2821 on Jan 30, 2025 | past |
|
| | Better obesity drugs are coming soon (baybridgebio.com) |
| 2 points by aaavl2821 on Oct 8, 2024 | past |
|
| | The Future of the Obesity Market (baybridgebio.com) |
| 1 point by aaavl2821 on Oct 3, 2024 | past |
|
| | The obesity drug landscape in one chart (baybridgebio.com) |
| 3 points by aaavl2821 on Aug 15, 2024 | past |
|
| | A primer on the obesity drug landscape (baybridgebio.com) |
| 2 points by aaavl2821 on Aug 13, 2024 | past |
|
| | AI-enabled biotech startup analysis (baybridgebio.com) |
| 1 point by aaavl2821 on Oct 30, 2023 | past |
|
| | Analyzing gene therapy startup in layman's terms (baybridgebio.com) |
| 1 point by aaavl2821 on Oct 27, 2023 | past |
|
| | AI Analysis of Biotech Startups (baybridgebio.com) |
| 2 points by aaavl2821 on Oct 20, 2023 | past |
|
| | AI investment analyst: initiating coverage on Neumora Therapeutics (baybridgebio.com) |
| 1 point by aaavl2821 on Oct 5, 2023 | past |
|
| | Quantifying risk / reward in biotech investing (baybridgebio.com) |
| 1 point by aaavl2821 on Sept 27, 2023 | past |
|
| | Valuing Biotech Licensing Deals (baybridgebio.com) |
| 1 point by aaavl2821 on July 10, 2023 | past |
|
| | Show HN: Value Biotech Licensing Deals (baybridgebio.com) |
| 2 points by aaavl2821 on July 6, 2023 | past |
|
| | Which VCs are still investing in biopharma? (baybridgebio.com) |
| 1 point by aaavl2821 on May 4, 2023 | past |
|
| | Biotech VC on pace for worst year since 2016 (baybridgebio.com) |
| 2 points by aaavl2821 on May 4, 2023 | past |
|
| | The biotech venture capital crunch (baybridgebio.com) |
| 1 point by aaavl2821 on April 12, 2023 | past |
|
| | Show HN: Interactive guide to valuing biotech companies (baybridgebio.com) |
| 2 points by aaavl2821 on March 22, 2023 | past |
|
| | Diagnosing the problem with biotech R&D (baybridgebio.com) |
| 2 points by aaavl2821 on Sept 21, 2022 | past |
|
| | Is Biotech Investing Sustainable? (baybridgebio.com) |
| 1 point by aaavl2821 on Sept 8, 2022 | past |
|
| | The next generation of biotech VCs (baybridgebio.com) |
| 1 point by vwoolf on Aug 12, 2022 | past |
|
| | The next generation of biotech VCs (baybridgebio.com) |
| 2 points by aaavl2821 on Aug 11, 2022 | past |
|
| | Will a Recession Save Biotech? (baybridgebio.com) |
| 2 points by aaavl2821 on July 21, 2022 | past |
|
| | Biotech platforms are out, products are back in (baybridgebio.com) |
| 16 points by aaavl2821 on June 20, 2022 | past | 2 comments |
|
| | Can big pharma buy every biotech startup? (baybridgebio.com) |
| 1 point by aaavl2821 on June 10, 2022 | past |
|
| | Biotech crossover investors facing steep losses (baybridgebio.com) |
| 2 points by aaavl2821 on June 7, 2022 | past |
|
| | Who is still investing in biotech startups? (baybridgebio.com) |
| 2 points by aaavl2821 on May 24, 2022 | past |
|
| | Biotech's New Normal (baybridgebio.com) |
| 2 points by aaavl2821 on May 12, 2022 | past |
|
| | The Biotech M&a Gap (baybridgebio.com) |
| 1 point by aaavl2821 on May 5, 2022 | past |
|
|
| More |
